Arrayit Corporation Announces Allergy Testing Partnerships with Major Allergy Therapeutics Providers
August 27 2018 - 5:30AM
Sunnyvale, Aug. 27, 2018 (GLOBE NEWSWIRE) -- August 27, 2018 -
Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences
and personalized medicine company, announces allergy testing
partnerships with multiple providers of allergen immunotherapy
products including sub-cutaneous, sublingual, and oral allergy
medicines designed to treat patients of allergy and asthma.
Allergen immunotherapy, a time-tested clinical approach, can reduce
or eliminate allergy and asthma symptoms by lowering the levels of
specific cellular proteins known as immunoglobulin E (IgE)
molecules that activate the immune system and trigger immune
responses. Through these partnerships, doctors prescribing Arrayit
allergy tests gain access to a portfolio of safe, effective and
convenient allergy medicines for their allergy and asthma patients,
including custom immunotherapy products formulated upon review of
quantitative allergy test results.
Arrayit recently completed an allergy testing pilot program for
a top retail chain, established a nationwide network of 1,700
allergy sales professionals, met with top officials at the United
States Food and Drug Administration (FDA) regarding FDA approval of
a major product line, reported the sale of clinical instrumentation
to the FDA, signed allergy testing contracts with a consortium of
178 medical clinics and received approval for in-store promotions
by a major retailer. Arrayit’s new therapeutics partners
provide a seamless solution to doctors who diagnose and treat the
more than 50 million Americans reporting allergic symptoms
annually.
Arrayit CEO Rene Schena states, “Partnering with major allergy
therapeutics companies provides proven treatment modalities for
physicians who also prescribe Arrayit’s allergy microarray tests.
Such test-treatment pairing is designed to afford supervised health
and wellness of individual patients through value-based
personalized medicine.”
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads
and empowers the research, biotechnology, pharmaceutical, clinical
and healthcare sectors through the discovery, development and
manufacture of proprietary life science and personalized medicine
products and services to advance biomedical research and improve
wellness and human health. Please visit www.arrayit.com for
more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such
as "expect", "believe", and "should". Although we believe our
expectations are reasonable, our operations involve a number of
risks and uncertainties that are beyond our control, and these
statements may turn out not to be true. Risk factors associated
with our business, including some of the facts set forth herein,
are detailed in the Company's public filings.
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Nov 2023 to Nov 2024
